HUDDINGE, Sweden, April 29, 2003 (PRIMEZONE) -- Medivir
- MIV-210 producing positive results in ongoing phase I trial.
- More opportunities for Cathepsin S inhibitor.
- Successes in the explorative activities in the preclinical discoveryhave given a several new projects.
- Lars Adlersson took up position as Medivir's CEO and President on1 March.
- Profit after financial items: SEK -38.6 (2.8) m. Net salesamounted to SEK 43.4 (86.6) m.
- CCS' net sales increased to SEK 42.1 (35.0) m. Profit after financial items was SEK 8.8 (3.1) m.
FORTHCOMING FINANCIAL INFORMATION
The Annual General Meeting will be on 29 April 2003 The Second-quarter Interim Report 2003 will be published on 9 July 2003. The Third-quarter Interim Report 2003 will be published on 23 October 2003.
Medivir's financial reports are available at its Website, www.medivir.se as of these dates, under the 'Financial Information' heading.
The Medivir Group
Medivir is an innovative, specialist research corporation that produces and develops pharmaceuticals. The company is located in Huddinge, Sweden and Cambridge, U.K. Medivir's research is focused on developing new drug compounds based on proteases and polymerases as target enzymes.
The group comprises Medivir AB, the subsidiaries Medivir UK Ltd. and CCS AB, plus second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB. CCS develops, manufactures and markets skin-care products and pharmaceuticals. Medivir has been quoted on the Stockholm Stock Exchange since 1996.
Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has four projects in clinical development phases, two of which are entering phase III after completing phase II. One project is in phase I and one is in phase II.
In the first stage, Medivir has some ten activities in explorative activities; the second, lead identification, encompasses three projects. The third stage, optimization, has one project, and two projects entering this phase. One project-MV026048-is in preclinical development, the stage closest to clinical development.
This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download:
http://www.waymaker.net/bitonline/2003/04/29/20030429BIT01210/wkr0001.doc
The full report
http://www.waymaker.net/bitonline/2003/04/29/20030429BIT01210/wkr0002.pdf
The full report